Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients
Author:
Funder
Cancer Research UK
Agence Nationale de la Recherche
Agència de Gestió d'Ajuts Universitaris i de Recerca
Instituto de Salud Carlos III
Wellcome Trust
Publisher
Elsevier BV
Subject
Hepatology
Reference29 articles.
1. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection;Marcellin;Liver Int,2019
2. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection;J Hepatol,2017
3. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study;Berg;J Hepatol,2017
4. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir;Hadziyannis;Gastroenterology,2012
5. Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B;Papatheodoridis;Hepatology,2018
Cited by 63 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Effect of nucleos(t)ide analogue discontinuation on the prognosis of HBeAg‐negative hepatitis B virus‐related hepatocellular carcinoma after hepatectomy: A propensity score matching analysis;Cancer Medicine;2024-08
2. Higher hepatitis B core-specific T cell response is associated with a lower risk of clinical relapse after discontinuation of oral antiviral treatment;Journal of Microbiology, Immunology and Infection;2024-08
3. HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B;Gut;2024-07-20
4. High end‐of‐treatment hepatitis B core‐related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy;Liver International;2024-07-15
5. Clinical trial: An open‐label, randomised trial of different re‐start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B;Alimentary Pharmacology & Therapeutics;2024-07-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3